Stockholm, August 22, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”), unlocking the potential of a new class of drugs – angiotensin II type 2 receptor agonists (ATRAGs), today reports that its clinical study investigating the EndoPAT® technology as a tool to assess the effect of C21 on endothelial function is complete and that […]
Stockholm, 9 June 2023 – Vicore Pharma Holding AB (publ) (“Vicore” or the “Company”) has completed directed share issuances of in total 29,875,000 shares at a subscription price of SEK 16.75 per share (the “Directed Issue”), through which the Company receives SEK 500 million before transaction costs. The subscription price was determined through an accelerated […]
Stockholm, June 7, 2023 – Vicore Pharma Holding AB (STO: VICO) (“Vicore”) today announces that the European Patent Office (EPO) has granted Vicore’s patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The European patent protection: • […]
Stockholm, May 23, 2023 – Vicore Pharma Holding AB (STO:VICO) (“Vicore”) today announces issuance of a new US patent protecting an improved C21 formulation based on enteric coated compositions. The drug candidate C21 is currently in a phase 2a trial in idiopathic pulmonary fibrosis (IPF). The patent provides strong protection in the US because the […]
Stockholm, May 19, 2023 – Vicore Pharma Holding AB (publ) (“Vicore”), unlocking the potential of a new class of drugs to stop disease progression and restore function, today announces an updated interim analysis of its AIR phase 2a trial with C21 in idiopathic pulmonary fibrosis (IPF). With 51 patients enrolled, the data demonstrates that C21 […]
